Literature DB >> 32127858

Prevalence of ECG abnormalities among adults with metabolic syndrome in a Nigerian Teaching Hospital.

Adeoye Abiodun1, Adebayo Oladimeji2, Tayo Bamidele3, Adebiyi Adewole4, Owolabi Mayowa5.   

Abstract

BACKGROUND: Co-existence of metabolic syndrome (MetS) and electrocardiography (ECG) abnormalities heightens the risk of sudden cardiac death. However, there is a gap in evidence of how ECG changes cluster among continental Africans with or without MetS.
METHODS: We included 491 participants with interpretable ECG tracings who were consecutively recruited into the Cardiovascular Risk Prediction Registry (CRP). CRP is a registry of newly presenting patients into cardiology clinic of the University College Hospital, Nigeria, with a main objective of cardiovascular risk stratification to prevent cardiovascular morbidity and mortality. Using the International Diabetic Federation (IDF) criteria they were divided into those with metabolic syndrome and non-metabolic syndrome.
RESULTS: Four hundred and ninety-one participants comprising 48.3% women with mean age 53.72±15.2 years who met the IDF criteria with complete ECG interpretations were analyzed with 44.2% (men 38.6%; women 50.2%) of the participants having MetS while 74% had ECG abnormalities. Compared to women, men had higher mean serum total cholesterol, creatinine, smoking, and alcohol use, family history of hypertension and diabetes mellitus, QT prolongation, LVH plus or minus strain pattern, and ECG abnormalities in general. Women were heavier, had higher heart rate and proportions of MetS. ECG findings among those with or without MetS were not significantly different. In men, IDF metabolic score was associated with conduction abnormalities (p=0.039) and combined ECG abnormality (p=0.042) which became more significant with an exclusion of QT prolongation (p=0.004). Also, IDF abdominal obesity was associated with QT prolongation (p=0.017), combined ECG abnormality (p=0.034) while HDLc correlated with ECG abnormalities (0.037) in men. There was no significant associations of components of metabolic syndrome with ECG abnormalities among women.
CONCLUSION: There was a high prevalence of MetS and abnormal ECG among the studied population. Abnormal ECG findings were more common in men with no differential association in people with or without MetS. However, a significant association existed between certain components of MetS and ECG abnormalities in men only. Male gender and HDLc were independent predictors of ECG Abnormalities.
© 2019 Abiodun et al.

Entities:  

Keywords:  Electrocardiography; africans; metabolic syndrome

Mesh:

Year:  2019        PMID: 32127858      PMCID: PMC7040350          DOI: 10.4314/ahs.v19i4.4

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


Introduction

Metabolic syndrome (MetS) is a constellation of cardiometabolic risk factors that contribute immensely to the burden of cardiovascular morbidity and mortality worldwide. The prevalence of MetS varies depending on the diagnostic criteria and study populations1–3. Due to epidemiologic transitions arising mainly from an unhealthy lifestyle, the incidence of MetS is on a steady rise in low and middle-income countries (LMICs), as well as high-income countries (HICs). Prevalence as much as 40% has been reported in some HICs, while in Nigeria it has been found to be about 30%4,5. This burden is expected to increase in near future with it attendant high risk of cardiovascular disabilities and sudden deaths6,7. Metabolic syndrome has been associated with sudden cardiac death (SCD).8 In ARIC (Atherosclerosis Risk in Communities) Study, compared with participants without MetS, those with metabolic syndrome independent of race and ethnicity, had approximately 70% increased the risk of sudden cardiac death. Elevated blood pressure, impaired fasting glucose and low -density lipoprotein cholesterol as Mets components were shown to be the independent determinants of SCD.9 Interestingly, each of the components of MetS such as dyslipidemia, elevated blood pressure, insulin resistance ± glucose intolerance, as well as abdominal obesity has been shown to cause cardiac structural damages and arrhythmias10–13. Coexistence, therefore of MetS and ECG abnormalities may increase the risk of sudden cardiac death. However, there is a paucity of data on the association of cardiac arrhythmias and metabolic syndrome.14 Early detection of these cardiac abnormalities using baseline 12 -lead ECG which is simple, noninvasive and cost -effective can help identify at-risk individuals for prompt and focused management. Studies differ on the prevalence and associations of components of MetS with ECG abnormalities. In certain populations, a high prevalence of ECG abnormalities in metabolic syndrome were reported10,15–18. While coronary artery disease and its attendant ECG changes have similar findings among Caucasians, and same are rarely reported among Africans19,20. Despite the huge burden of stroke, heart failure and kidney failure in sub-Sahara Africa (SSA), data on ECG changes among metabolic syndrome patients alone are lacking. In order to address this gap and to show how ECG changes cluster among Africans with MetS, we report ECG changes in a Nigerian population with MetS compared to those without MetS.

Methods

Subjects and methods

This cross-sectional and comparative study was conducted over a period of one year from July 2014 to June 2015 following approval by the Joint University of Ibadan (UI)/University College Hospital (UCH) Ethics Committee approval reference number UI/EC/14/0136 dated 19th June 2014. Four hundred and ninety-one adult patients with complete data for the diagnosis of metabolic syndrome and interpretable ECG tracings from CRP registry were studied. Cardiovascular Risk Prediction (CRP) is a registry of newly presenting patients into the cardiology division, medical out-patient department of University College Hospital Ibadan. The main aim of the registry is to risk stratify the patients at entry using Framingham and QRISK2 cardiovascular risk score for prompt management of at-risk individuals to prevent future cardiovascular morbidity and mortality. Biodata of the participants was obtained using pretested questionnaires containing information on demographics, family history of cardiovascular diseases, life-styles and medication history. The contact information of the participants and their next of kin were obtained for communication during follow-up.

Assessment of anthropometric measurement

Anthropometric measurements including height, weight, waist and arm circumferences were obtained by trained nurses at the medical outpatient clinic. Height was measured without shoes to the nearest centimeter using a ruler attached to the wall. Weight was measured to the nearest 0.1kg on an electronic scale, with the subject wearing light outdoor clothing. Waist circumference was measured at the end of expiration at a mid-way between the rib cage and the iliac crest using an anthropometric measuring tape. Average of three measured waist circumferences, recorded to the nearest tenth of a centimeter was obtained for analysis. Obesity was classified based on BMI in kg/m2 as normal (>20 and <25), overweight (>25 and <30), obesity (>30 and <35) and severe obesity (≥35)21. Abdominal obesity was defined based on the International Diabetic Federation (IDF) criteria using waist circumference (≥94cm (men), ≥80cm (female). Participants were further categorized as normal risk (men <94cm; women <80 cm), increased risk (men 94–102cm; women 80–88 cm), or substantially increased risk (men >102cm; women >88 cm) on the basis of the World Health Organization's standards for increased health risk associated with waist circumference22,23.

Assessment of blood pressure

The clinic blood pressure was measured in a relaxed sitting position using a standard Omron (HEM711DLX) with blood pressure apparatus on the left arm, placed at heart level after 5-minute rest and using a cuff of appropriate size with legs uncrossed. Three BP measurements were obtained with a minimum interval of one minute and average of the last two measurements was used in the present analysis. Hypertension was defined as systolic blood pressure (SBP) ≥ 140mmHg and/or diastolic blood pressure (DBP) ≥ 90mmHg or being on antihypertensive treatment.

Electrocardiography

All participants for this study had resting 12-lead ECG, using a commercially available CONTEC® Workstation Model CONTEC EC8000G, ECG machine (Made in China) at speed of 25mm/s and 1mV/cm calibration. The entire ECG tracing used were inspected visually by the blinded ECG technicians in our non-invasive cardiology laboratory to detect technical errors, unrecorded leads and inadequate quality of tracings. Defective ones are repeated before data was extracted for use in the study. The ECG tracings were independently analyzed by the cardiologists who were unaware of the details of the clinical status of the patients. Abnormalities obtained from the ECGs were defined according to standard criteria24,25 (Table 1). Left ventricular hypertrophy was diagnosed using the following criteria: Sokolow-Lyon voltage (sum of the amplitudes of S wave in V1 and R wave in V5 or V6 ≥3.5 mV). Repolarization abnormalities in leads V5 and/or V6 indicated typical strain when there was down-sloping convex ST segment with an inverted asymmetrical T-wave opposite to the QRS axis26,27. QT interval was determined using the tangent method28. The measured QT interval was corrected for heart rate using the Bazett's formula. Prolonged QT interval was considered present when the QTc was >450 milliseconds and >440milliseconds in women and men respectively. Presence of other ST-T changes was documented according to standard criteria24.
Table 1

Definitions of ECG Variables

ECG VariablesDefinitions
Atrial fibrillation(Afib)Coarse fibrillatory waves, irregular QRS, rate 400–500 beats per minutes
Atrial flutter(Afl)Rate between 250 to 350 beats per minute, saw tooth pattern P waves
Sinus arrhythmiaVariation of the P-P interval, from one beat to the next, of at least 0.12 seconds, or 120 milliseconds
Premature Ventricular Contraction(PVC)Abnormal QRS shape and QRS=≥120ms
Premature Supra ventricular contraction(PSVC)Presence of sinus tachycardia, atrial tachycardia, atrial fibrillation, AVNRT complexes, atrial flutter, multifocal atrial tachycardia, accelerated junctional tachycardia
Left atrial enlargement(LAE)P wave in lead II is greater than ≥ 120ms
Bi-atrial enlargement(BAE)P wave in lead II is greater than 120ms and higher than ≥ 2.5mm
Left Ventricular hypertrophy(LVH)Sokolow-LyonSV-I + RV-5 or RV-6 = ≥35 mm (whether male or female)
Left Ventricular hypertrophy with strainSV-I + RV-5 or RV-6 = ≥35 mm (whether male or female) with T waves changes
Right Ventricular hypertrophy(RVH)R/S ratio of greater than 1 in lead V1 in the absence of other causes or if the R wave in lead V1 is greater than 7 millimeters tall
P duration≤0.120seconds
QRS duration0.80–0.120seconds
PR interval0.12–0.20seconds
QT Interval0.40 seconds (for males) and 0.44 seconds (for females)
Definitions of ECG Variables

Definition of metabolic syndrome

Metabolic syndrome was defined based on International Diabetic Federation (IDF) criteria using waist circumference (≥94cm (men), ≥80cm (female), or two or more of the following. i) Fasting triglyceride >150g/dL or specific treatment for this lipid abnormality. ii) HDL cholesterol < 40mg/dL(men), <50mg/dL(women) or specific treatment for this lipid abnormality. iii) Blood pressure >130mmHg (systolic), >90mmHg (diastolic) or on anti-hypertensive treatment. iv)fasting plasma glucose ≥100 mg/dL or previously diagnosed diabetes mellitus.29

Data management and statistical analysis

The data was analyzed using Statistical Package for Social Sciences (SPSS), version 20.0 (IBM). The qualitative data were summarized as frequency and percentage while quantitative variables was summarized as means and standard deviations (SD). To investigate the statistical significance of the difference in continuous variables according to gender and the presence of metabolic syndrome or not, independent samples t-test was employed. For categorical variables, the Chi-square test for the comparison of proportions was employed. Association between selected demographic, clinical characteristics and ECG findings was investigated at bivariate and multivariate levels with p-value <0.05.

Results

Four hundred and ninety-one participants comprising 48.3% women with mean age 53.72±15.2 years who met the IDF criteria with complete ECG interpretations were analyzed. 44.2% (men 38.6%; women 50.2%) and 74% of the participants had MetS and ECG abnormalities respectively. As shown in Table 2 and 3, mean age, blood pressure parameters and waist circumference were comparable across gender. Compared to women, men had higher mean total cholesterol, creatinine, smoking, and alcohol use, and diabetes mellitus, QT prolongation, LVH plus or minus strain pattern, and ECG abnormalities in general. Women were heavier, had higher heart rate and proportions of MetS. Expectedly, participants with MetS compared with those without MetS had higher mean blood pressure, waist circumference, BMI, Triglyceride, fasting plasma glucose and smoking history. ECG findings were similar among the group.
Table 2

Characteristics of Study Participant by Gender

VariablesTotal 491 (100%)Male 254 (51.7%)Female 237 (48.3%)p- Value
Age (years)53.72±15.254.37±15.553.03±14.80.328
Alcohol Use (%)130 (26.5)90 (35.4)40 (16.9)<0.0001
Ex-Smoker (%)114 (23.2)82 (32.3)32 (13.5)<0.0001
Current Smoker (%)3 (0.6)3 (1.2)0 (0.0)
Hip Circumference (cm)102.13±14.799.68±13.6104.77±15.5<0.0001
Waist Circumference (cm)93.09±14.891.97±15.694.30±13.80.081
Body Mass Index (Kg/m2)27.34±5.825.80±4.928.98±6.1<0.0001
Systolic Blood Pressure (mmHg)144.53±24.4145.33±24.0143.65±24.80.449
Diastolic Blood Pressure (mmHg)89.13±16.589.75±17.188.44±15.80.381
Fasting Blood Sugar (mg/dL)98.97±36.0102.02±41.195.71±29.40.069
Urea (mg/dL)28.30±17.630.28±21.026.26±12.80.013
Creatinine (mg/dL)1.31±1.11.25±0.81.01±1.30.014
Total Cholesterol (mg/dL)185.28±45.6180.14±46.4190.98±44.00.011
Triglyceride (mg/dL)100.99±39.4102.90±45.198.89±32.00.275
Low Density Lipoprotein Cholesterol mg/dL)117.15±38.2114.07±37.8120.55±38.40.069
High Density Lipoprotein (mg/dL)47.18±17.3444.94±16.049.66±18.40.003
ECG Changes
Heart Rate (beat/minute)84.01±18.381.74±17.586.38±19.00.008
P Duration (ms)113.10±31.2111.94±30.1114.23±32.30.445
QRS Duration (ms)113.64±30.8115.51±30.1111.71±31.40.197
T Duration (ms)266.04±44.0266.41±42.2265.68±45.80.890
PR Interval (ms)151.38±35.7150.10±33.7152.63±37.50.471
QT Interval (ms)405.43±48.7405.32±46.0405.54±51.50.963
QTc Interval (ms)475.71±70.5469.46±71.3482.13±69.30.061
LVH (%)153 (32.7)92 (38.2)61 (26.9)0.009
LVH with Strain Pattern (%)44 (9.5)34 (14.4)10 (4.4)<0.0001
Prolonged QT (%)269 (58.0)150 (62.8)119 (52.9)0.031
ECG Abnormalities (%)356 (74.0)199 (79.9)157 (67.7)0.002
Diabetes Mellitus (%)35 (8.1)25 (11.2)10 (4.8)0.014
MetS (%)217 (44.2)98 (38.6)119 (50.2)0.010
Table 3

Basic Demographic and Clinical Parameters versus Metabolic Syndrome

VariablesTotal 491 (100%)Non-Metabolic Syndrome (NMetS) 274 (55.8%)Metabolic Syndrome (MetS) 217 (44.2%)p-Value
Age (years)53.72±15.253.06±16.754.57±13.00.262
Alcohol Use (%)130 (26.5)72 (26.3)58 (26.7)0.430
Smoking StatusFormer Smoker (%)114 (23.2)76 (27.7)38 (17.5)0.030
Current Smoker (%)3 (0.6)0 (0.0)3 (1.4)
OccupationProfessional (%)138 (28.1)65 (23.7)73 (33.6)0.001
Unskilled (%)4 (0.8)2 (0.7)2 (0.9)
Hip Circumference (cm)102.13±14.797.28±14.7108.26±12.3<0.0001
Waist Circumference (cm)93.09±14.887.24±13.8100.48±12.5<0.0001
Hip Waist Ratio6.00±65.49.12±88.12.36±15.20.418
Body Mass Index (Kg/m2)27.34±5.825.31±5.329.93±5.3<0.0001
Waist Height Ratio0.58±0.30.54±0.20.63±0.4<0.0001
Waist Hip Ratio0.93±0.40.92±0.50.93±0.10.787
Systolic Blood Pressure (mmHg)144.53±24.4139.57±24.7150.69±22.5<0.0001
Diastolic Blood Pressure (mmHg)89.13±16.586.50±16.792.39±15.6<0.0001
Fasting Blood Glucose (mg/dL)98.97±36.094.72±37.5103.94±33.70.008
Urea (mg/dL)28.30±17.628.92±21.227.55±11.50.401
Two Hours Fasting Blood Sugar (mg/dL)121.06±55.0111.82±49.2130.55±59.00.010
Creatinine (mg/dL)1.13±1.11.121±0.81.14±1.390.821
Total Cholesterol (mg/dL)185.28±45.6184.85±46.5185.76±44.60.831
Triglyceride (mg/dL)100.99±39.493.54±35.0109.45±42.4<0.0001
Low Density Cholesterol (mg/dL)117.15±38.2115.49±38.5119.03±37.80.320
High Density Lipoprotein (mg/dL)47.18±17.350.95±19.042.94±14.1<0.0001
Characteristics of Study Participant by Gender Basic Demographic and Clinical Parameters versus Metabolic Syndrome Tables 4, 5 and 6 depict gender differences in ECG changes and Components of MetS. In men IDF metabolic score was associated with conduction abnormalities (p=0.039) and combined ECG abnormality (p=0.042) which became more significant with the exclusion of QT prolongation (p=0.004). Also, IDF abdominal obesity was associated with QT prolongation (p=0.017), combined ECG abnormality (p=0.034), and HDLc with ECG abnormalities (0.037). No significant associations of components of metabolic syndrome with ECG abnormalities among women. Table 7 shows that male gender and HDLc were independent predictors of ECG Abnormalities.
Table 4

Comparisons of ECG abnormalities in metabolic syndrome

VariablesTotalNon-Metabolic SyndromeMetabolic Syndromep-
491 (100%)274 (55.8%)217 (44.2%)Value
P Duration (ms)113.10±31.2111.77±33.5114.61±28.40.356
QRS Duration (ms)113.64±30.8115.04±32.6112.02±28.50.306
T Duration (ms)266.04±44.0267.63±47.6264.19±39.50.515
PR Interval (ms)151.38±35.7151.23±37.1151.55±34.10.927
QT Interval (ms)405.43±48.7407.18±51.3403.42±45.60.423
QTc Interval (ms)475.71± 70.5479.64± 79.9471.20±57.90.203
Left Atrial Enlargement (%)47 (9.6)28 (10.2)19 (8.8)0.787
Bi-Atrial Enlargement (%)11 (2.2)7 (2.6)4 (1.8)0.789
LVH (%)153 (31.2)93 (33.9)60 (27.6)0.324
LV Strain Pattern (%)44 (9.0)26 (9.5)18 (8.3)0.885
RV Hypertrophy (%)12 (2.4)9 (3.3)3 (1.4)0.385
Prolonged QT interval (%)269 (58)146 (57.6)123 (58.6)0.85
ECG Abnormalities (%)356 (74.0)200 (74.3)156 (73.6)0.917
ECG Abnormalities {Without255 (53.6)152 (57.4)103 (48.8)0.065
QT Abnormality} (%)
Table 5

Gender specific characteristics in metabolic syndrome

VariablesMalep-ValueFemalep-Value


Non- MetabolicMetabolicNon- MetabolicMetabolic
Age (years)53.34±17.156.03±12.60.18152.68±16.253.36±13.20.724
Body Mass Index (kg/m2)23.87±4.328.93±4.2<0.000127.22±5.930.73±5.9<0.0001
Hip Circumference (cm)94.67±12.9107.65±10.7<0.0001100.74±16.3108.76±13.5<0.0001
Waist Circumference84.81±12.5103.37±12.9<0.000190.45±14.898.11±11.9<0.0001
(cm)
Systolic Blood Pressure140.94±24.1152.29±22.3<0.0001137.73±25.5149.38±22.7<0.0001
(mmHg)
Diastolic Blood Pressure87.58±16.693.19±17.40.01185.04±16.891.73±14.10.001
(mmHg)
Fasting Blood Sugar98.03±46.0108.25±31.30.07090.07±19.6100.59±35.10.010
(mg/dL)
Urea (mg/dL)30.71±25.229.63±12.30.70026.68±14.725.84±10.60.620
Creatinine (mg/dL)1.28±0.91.22±0.40.5460.93±0.41.09±1.80.362
Total Cholesterol176.23±45.8185.89±46.90.112197.15±44.8185.66±42.80.054
(mg/dL)
Triglyceride (mg/dL)94.97±38.1114.56±51.90.00191.50±30.1105.20±32.30.001
Low Density Cholesterol111.67±36.5117.59±39.50.232120.93±40.7120.23±36.50.893
(mg/dL)
High Density Lipoprotein46.92±15.442.05±16.70.02056.65±22.143.67±11.6<0.0001
(mg/dL)
Heart Rate83.26±17.779.57±17.00.12086.35±18.986.41±19.10.982
(beats/minutes)
P Duration (ms)112.01±33.7111.84±24.30.968111.49±33.4116.81±31.20.233
QRS Duration (ms)113.85±32.2117.85±26.90.332116.53±33.2107.19±28.90.029
T Duration (ms)267.62±42.9264.85±41.60.704267.64±2.5263.63±37.90.602
PR Interval (ms)151.26±35.4148.52±31.40.566151.19±39.1153.99±36.10.590
QT Interval (ms)404.36±49.8406.67±40.20.713410.67±53.1400.73±49.70.158
QTc Interval (ms)471.51±78.6466.59±59.90.614489.71±80.7475.02±56.10.121
Table 6

Gender specific association between components of metabolic syndrome and ECG Abnormality

VariablesMalep-ValueFemalep-Value


ECG- AbnormalityNo ECG- AbnormalityECG- AbnormalityNo ECG- Abnormality
IDF- Abdominal Obesity (%)101 (50.8)17 (34.0)0.034135 (86.0)69 (92.0)0.189
IDF-Blood Pressure (%)170 (81.3)39 (78.0)0.173122 (78.2)55 (75.3)0.630
IDF-Glucose (%)64 (36.8)12 (26.1)0.17537 (26.8)15 (28.8)0.460
IDF-Triglceride (%)21 (11.0)5 (10.4)0.9089 (6.3)6 (8.6)0.533
IDF-HDLc (%)134 (70.5)41 (85.4)0.03787 (60.4)47 (67.1)0.340
Table 7

Determinants of ECG abnormalities in the study population

VariableOdd ratio95% Confidence IntervalP value
Age1.0060.990 – 1.0220.460
Male Gender1.9041.126 – 3.2200.016
IDF_Abdominal Obesity0.9440.540 – 1.6510.839
MS_Blood Glucose0.8250.490 – 1.3890.469
MS_Blood Pressure0.8370.461 – 1.5190.558
MS_High Density Lipoprotein1.8431.068 – 3.1800.028
MS_Triglyceride1.1720.517 – 2.6610.704
Comparisons of ECG abnormalities in metabolic syndrome Gender specific characteristics in metabolic syndrome Gender specific association between components of metabolic syndrome and ECG Abnormality Determinants of ECG abnormalities in the study population

Discussion

In this study, approximately 4 out of 10 participants had MetS while three quarters had ECG abnormalities. Abnormal ECG findings were commoner in men with no differential association in people with MetS and those without MetS. However, a significant association existed between certain components of MetS and ECG abnormalities in men only. The prevalence of 44.2% in this current study is almost twice the prevalence earlier reported by our team among the health workers. While women had excess MetS in both study cohorts, the gaps appear closing up among the gender, “34.9% vs 2.4% among health workers as against 50.2% vs 38.6%.”30. Similarly, our finding of a high proportion of MetS was higher than others reported in Nigerian communities31. The rising trends may not be unconnected with equally increasing components such as obesity, hypertension, dyslipidemias and insulin resistance resulting from unhealthy lifestyles and epidemiologic transition32. May also be due to the fact that it was prevalence at a referral clinic. Contrary to our findings, probably due to the influence of wealth and intake of atherogenic diets, Barrios and colleagues in Spain,33 Ford and colleagues34 in the United States, and Yassein and colleagues35 in Jordan reported higher prevalence rates of 52%, 62.9%, and 52%, respectively. With a high proportion of metabolic syndrome components (high BP, 80.7%; central obesity, 67%; low HDL, 68.7% and hyperglycemia, 30%) in this cohort, MetS incidences will soon rival those of HICs. Apparently, our study population requires urgent care to prevent a possible escalation of stroke, heart failure, and Myocardial infarction associated with increasing prevalence of MetS. Abnormalities in resting electrocardiograph (ECG) have been strongly associated with cardiovascular morbidity and mortality.36 Its coexistence with MetS potentiates the rate of sudden cardiac deaths.37 In this study, we report a high prevalence of ECG abnormalities and MetS. There was no association between MetS and ECG abnormalities. However, central obesity and low HDL were significantly associated with ECG abnormalities in men. Similar to our findings, Ebong et.al in MESA study reported a high prevalence of ECG in Mets which were gender specific38. However, they found associations between ECG abnormalities and MetS and its components; high blood pressure and triglyceride. The reasons for these discrepancies were not immediately obvious. Our finding, showing no association between ECG changes and MetS is similar to an earlier study in Nigeria17. Apart from the larger population in our study, gender-specific association between components of MetS and ECG abnormalities was not explored, which our study showed. Similarly, a study in African Americans which share ancestry with blacks in sub-Saharan Africans showed high a proportion of ECG changes among their study population, so also among Caucasians16,39,40. Our study specifically showed a high prevalence of prolonged QTc, left ventricular hypertrophy (LVH) and LVH with strains abnormality similar to other studies16. This is not surprising since studies have shown high preponderance of LVH among blacks.41,42. Left ventricular hypertrophy is an independent risk factor for stroke. Prolongation of the QT and QTc intervals is caused by the heightened sympathetic activity characteristic of obesity that increases the reduced heart rate variability; all these elements have the potential to cause arrhythmia and may lead to cardio-embolic stroke. Previous studies have established the role of uncontrolled elevated blood pressure and other traditional cardiovascular risk factors in structural myocardial changes which are interpreted from ECG recordings43. The aggregates of these risk factors which constitutes MetS are suspected to produce more abnormal ECG changes in people with MetS compared with those without MetS. Our study did not have significant changes between the two groups. However, certain components of MetS were significantly different among men only. High frequency of hypertension among the groups may account for the insignificant ECG findings. The implication of our findings to clinical care is that people referred for cardiac care in our center who have high aggregates of cardiovascular risk factors should have an ECG done at presentation. This is because of the high prevalence of significant abnormalities which may be due to high prevalence of hypertension and dyslipidemia, the most important drivers of ECG changes, especially among blacks.17,44,45

Strengths and limitation

Our study has several strengths; one of such is establishing the burden of metabolic syndrome and abnormal ECG among the first timer at a cardiac clinic in Nigeria. Our findings have implications for early risk stratification of our patients for prompt management. However, the cross-sectional study design is a limitation, as the causal relationship cannot be established. Also the use of Sokolow Lyon criteria which is non sex-specific might have exaggerated our findings of LVH in men. In addition, the small sample size and hospital-based data collection limit the generalization of our findings to the general population.

Conclusion

MetS and abnormal ECG changes are common among the studied population. While women had a higher prevalence of MetS, men had more abnormal ECG findings with a significant association between abdominal obesity, dyslipidemia and ECG abnormalities in men only. Larger prospective study is required to support gender - specific cardiac care in this population.
  38 in total

Review 1.  Pathophysiological dilemma of syndrome X.

Authors:  R O Cannon; P G Camici; S E Epstein
Journal:  Circulation       Date:  1992-03       Impact factor: 29.690

Review 2.  A proposed clinical staging system for obesity.

Authors:  A M Sharma; R F Kushner
Journal:  Int J Obes (Lond)       Date:  2009-02-03       Impact factor: 5.095

3.  The measurement of the Q-T interval of the electrocardiogram.

Authors:  E LEPESCHKIN; B SURAWICZ
Journal:  Circulation       Date:  1952-09       Impact factor: 29.690

4.  Electrocardiographic abnormalities associated with the metabolic syndrome and its components: the multi-ethnic study of atherosclerosis.

Authors:  Imo A Ebong; Alain G Bertoni; Elsayed Z Soliman; Mengye Guo; Christopher T Sibley; Yii-Der I Chen; Jerome I Rotter; Yi-Chun Chen; David C Goff
Journal:  Metab Syndr Relat Disord       Date:  2011-11-04       Impact factor: 1.894

5.  Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study).

Authors:  Rikki M Tanner; Usman Baber; April P Carson; Jenifer Voeks; Todd M Brown; Elsayed Z Soliman; Virginia J Howard; Paul Muntner
Journal:  Am J Cardiol       Date:  2011-04-29       Impact factor: 2.778

6.  Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis.

Authors:  Vivencio Barrios; Carlos Escobar; Alberto Calderón; José L Llisterri; Eduardo Alegría; Javier Muñiz; Arantxa Matalí
Journal:  J Cardiometab Syndr       Date:  2007

7.  Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study.

Authors:  J C Kaski; G M Rosano; P Collins; P Nihoyannopoulos; A Maseri; P A Poole-Wilson
Journal:  J Am Coll Cardiol       Date:  1995-03-15       Impact factor: 24.094

8.  ELECTROCARDIOGRAPHIC ABNORMALITIES AMONG MEXICAN AMERICANS: CORRELATIONS WITH DIABETES, OBESITY, AND THE METABOLIC SYNDROME.

Authors:  Saulette R Queen; Beverly Smulevitz; Anne R Rentfro; Kristina P Vatcheva; Hyunggun Kim; David D McPherson; Craig L Hanis; Susan P Fisher-Hoch; Joseph B McCormick; Susan T Laing
Journal:  World J Cardiovasc Dis       Date:  2012-04

9.  Excess Metabolic Syndrome Risks Among Women Health Workers Compared With Men.

Authors:  Abiodun M Adeoye; Ifeoluwa A Adewoye; David M Dairo; Adewole Adebiyi; Daniel T Lackland; Gbenga Ogedegbe; Bamidele O Tayo
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-06-06       Impact factor: 3.738

10.  Association of metabolic syndrome and electrocardiographic markers of subclinical cardiovascular disease.

Authors:  Theodora W Elffers; Renée de Mutsert; Hildo J Lamb; Arie C Maan; Peter W Macfarlane; Ko Willems van Dijk; Frits R Rosendaal; J Wouter Jukema; Stella Trompet
Journal:  Diabetol Metab Syndr       Date:  2017-05-22       Impact factor: 3.320

View more
  3 in total

1.  Patterns and associated factors of electrocardiographic abnormality among type 2 diabetic patients in Amhara National Regional State Referral Hospitals, Ethiopia: a multicenter institution-based cross-sectional study.

Authors:  Deresse Sinamaw; Mihret Getnet; Mohamed Abdulkadir; Kassa Abebaw; Mohammed Ebrahim; Mengistie Diress; Yonas Akalu; Adugnaw Ambelu; Baye Dagnew
Journal:  BMC Cardiovasc Disord       Date:  2022-05-19       Impact factor: 2.174

2.  Stage 2 Hypertension and Electrocardiogram Abnormality: Evaluating the Risk Factors of Cardiovascular Diseases in Nigeria.

Authors:  Shalom Nwodo Chinedu; Franklyn Nonso Iheagwam; Michael Kemjika Onuoha; Grace Nkechi Joshua; Opeyemi Christianah DeCampos
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-02-04

3.  Prevalence of major and minor electrocardiographic abnormalities and their relationship with cardiovascular risk factors in Angolans.

Authors:  Mauer A A Gonçalves; João Mário Pedro; Carina Silva; Pedro Magalhães; Miguel Brito
Journal:  Int J Cardiol Heart Vasc       Date:  2022-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.